William O'Connor - Stern Investor Relations Peter Nielsen - President and Chief Executive Officer Ulrich Mueller - Chief Operating Officer Anthony Price - Director of Finance and Accounting.

Jason McCarthy - Maxim Yi Chen - H.C. Wainwright.

Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings’ Second Quarter 2016 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Will O'Connor of Stern Investor Relations. Please proceed..

Thank you, operator. My name is Will O'Connor of Stern Investor Relations. I'd like to welcome you to the Bio-Path Holdings conference call and webcast to review the company's second quarter 2016 financial results and to provide an update on recent pipeline and corporate developments.

Earlier today, we issued a press release, which outlines the topics that we plan to discuss today. The release is available at biopathholdings.com. With me today from Bio-Path are President and CEO Peter Nielsen, COO Dr. Ulrich Mueller, COO and Anthony Price, Director of Finance and Accounting.

Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we urge you to read.

Our actual results may vary materially from what is discussed on today's call. With that, I'll now turn the call over to Bio-Path's CEO, Peter Nielsen..

Oligonucleotide and Peptides Therapeutics Conference. In June, we were delighted to have data from the Phase I study of BP1001 as a treatment for AML and CML and the safety segment of the Phase II combination therapy of BP1001 in combination with low dose cytarabine as a treatment for advanced AML presented by Dr.

Maro Ohanian, Assistant Professor at the University of Texas MD Anderson Cancer Center, in a poster titled, “Phase I Study of BP1001 Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies” at the 2016 ASCO Annual Meeting.

These statement reported from the dose finding immunotherapy portion of Cohorts 1 through 6 of the Phase I study of BP1001 at doses up to 90 milligram per square meter in refractory/relapsed leukemia patients as well as on the safety segment of the Phase II study which evaluated the toxicity of BP1001 in Cohort 7 and 8 in doses of 60 milligram per square meter and 90 milligram per square meter combined with low dose Ara-C chemotherapy in refractory/relapsed patients with advanced AML.

Data from the safety segment of the Phase II combination therapy of BP1001 and low dose Ara-C showed no dose limiting toxicities. Of the six valuable patients, four patients completed more than two cycles of treatment, treat patients achieved complete remission and two patients achieved partial remission.

In addition, the pharmacokinetic of BP1001 demonstrated a half-life at 60 milligram per square meter of 30 hours.

During the second quarter we also entered into a sponsored research agreement with Thomas Jefferson University to investigate the DNAbilize antisense DNA technology for the development of the brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. The research is being led by Dr. D.

Craig Hooper, Ph.D., Department of Cancer Biology, Sidney Kimmel Cancer Center at Thomas Jefferson University who previously evaluated our DNAbilize antisense technology in preclinical studies that demonstrated efficacy suggesting the potential for a systematic antisense immunotherapy for brain cancers.

This is important work, as brain cancer such as glioblastoma are very aggressive, have limited treatment options and poor survival rates, making it an indication for which novel treatments are urgently needed. We are excited to continue our work with Dr. Hooper and look forward to reporting our progress with these studies.

It’s been an exciting and productive first half of 2016, importantly we raised $10 million in registered direct offering. This financing supports that continue development of our very promising platform technology and pipeline.

We expect to continue to make meaningful progress throughout the balance of the year and look forward to achieving several value created milestones. With that, I’ll now turn the call over to Anthony Price for a brief overview of our financials..

Thank you, Peter. Company reported a net of $1.9 million or $0.02 per share for the three months ended June 30, 2016 compared to a net loss of $1.1 million or $0.01 per share for the same period of 2015. This increase was primarily due to the release of drug material in preparation for our Phase II clinical trial for BP1001 in AML.

Research and development expense for the three months ended June 30, 2016, increased to $1.2 million compared to $0.6 million for the same period in 2015. General and administrative expense for the three months ended June 30, 2016 increased to $0.8 million compared to $0.6 million for the same period in 2015.

As of June 30, 2016, the company had cash of $4.2 million compared with $8.9 million at December 31, 2015. Net cash used in operating activities for six months ended June 30, 2016 was $4.6 million compared to $2.8 million for the comparable period in 2015. As Peter noted earlier, the company recently completed a $10 million registered direct offering.

Note, that these results do not include funds raised from the offering..

With that overview operator, we are ready to open the call for questions..

Thank you. [Operator Instructions] Our first question comes from Jason McCarthy with Maxim. Your line is open..

Hi Peter, how are you? We’re looking forward to the trial in AML initiating in that first patient dose.

Can you tell us, once you hit that 19 patient mark how long will it take to see data and what is it going to take to convert potential to a registration study and how many patients would that be?.

Let me have, Ulrich, maybe you can specifically respond to those parameters that Jason is asking..

Yes, I’d be happy to. So, once we have the 19 patients enrolled with dose we should be able to do the analysis fairly quickly within about a month or two. We will be working with the regulatory agency prior to that to make sure that to design a trial that’ll be moving to the registration trial right now.

So looking – if we go into the registration file with a control arm it would exactly about 196 patients..

Okay, thank you.

And could you just remind us and walk us through plans for 1002, and where that program or just an update on that program?.

Yes, that program is continuing to proceed towards I&D filing, we are in the process of finalizing the CMC for the I&D, so we look to have that filed up towards the end of the year or in 2017..

Okay, thank you Ulrich. Thanks for taking the question..

Thank you. Our next question comes from Yi Chen with H.C. Wainwright. Your line is open..

Hi, thank you for taking my questions.

Can you give us an update on BP1001 for the treatment of CML? Is it going to be a Phase II safety segment trial starting soon?.

Great question.

Again Ulrich, would you take that please?.

Yes, yes. Yeah, the protocol has been submitted to the [indiscernible] for review so we hope we are being in the safety portion of that trial, they’re running to the full Phase II within a month or two..

Okay.

And also could you give us an additional color regarding FDA’s perspective, so as I understand – if I understand correctly, so for the ultimate approval for BP1001 for the treatment of AML you still need to show survival benefits in the registration trial, correct?.

Yes..

Okay.

So, but with the 19 patients, if there is a good response result for the 19 patient and FDA is okay that you can switching to – converting to a registration trial?.

Yeah, subsequent..

Okay, thank you..

Thank you. I’m showing no further questions. I’d like to turn the call back to Peter Nielsen for closing remarks..

Well, thank you. Thank you all for joining us this morning and for your continued interest and support. We look forward to building on our momentum and addressing you in our next quarterly update. Have a great day..

Ladies and gentlemen, thank you for participating in today's conference. This concludes the program and you may all disconnect. Everyone have a good day..